Evidence for Boswellia in Low-Grade Ulcerative Colitis

Guideline Recommendations

The American Gastroenterological Association recommends against using Boswellia serrata for ulcerative colitis, due to uncertain benefit-risk balance, no quality of life improvement, and higher adverse event rates 1, 2
The AGA explicitly advises against Boswellia serrata treatment for inflammatory bowel conditions based on their systematic review of the evidence 1, 3
The rationale for recommending against its use includes a single randomized controlled trial showing only 44% of patients treated with Boswellia serrata improved clinically compared to 27% in the placebo arm, with no statistically significant difference 1
Numerous Boswellia products are available without standardized formulations, making consistent dosing and quality control impossible 1, 2

The evidence supporting Boswellia for any form of colitis is low quality at best 1, 3
A Cochrane systematic review found that one study of Boswellia serrata extract showed a clinical response in 44% versus 27% with placebo, but this difference was not statistically significant (RR 1.64, 95% CI 0.60 to 4.49) 1

For mild-to-moderate ulcerative colitis, the evidence-based treatment algorithm includes first-line standard-dose mesalamine (2-3 g/day) or high-dose mesalamine (>3 g/day) 4, 5
Mesalamine enemas or suppositories are superior to oral therapy for proctitis/proctosigmoiditis 4
If refractory to 5-ASA, add oral prednisone or budesonide MMX 4, 7
Budesonide should not be used for long-term maintenance in ulcerative colitis 7
The evidence for mesalamine is high quality with clear dose-response relationships: high-dose mesalamine (>3g/day) reduces failure to induce remission by 225 fewer per 1,000 patients compared to placebo (RR 0.75, 95% CI 0.65 to 0.86) 5